CN110177572A - 用于治疗痴呆的组合物 - Google Patents

用于治疗痴呆的组合物 Download PDF

Info

Publication number
CN110177572A
CN110177572A CN201780055706.XA CN201780055706A CN110177572A CN 110177572 A CN110177572 A CN 110177572A CN 201780055706 A CN201780055706 A CN 201780055706A CN 110177572 A CN110177572 A CN 110177572A
Authority
CN
China
Prior art keywords
estradiol
acid
dementia
isoflavones
composition described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780055706.XA
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·霍夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210417996.0A priority Critical patent/CN114796236A/zh
Publication of CN110177572A publication Critical patent/CN110177572A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780055706.XA 2016-09-12 2017-09-08 用于治疗痴呆的组合物 Pending CN110177572A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210417996.0A CN114796236A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US62/393,140 2016-09-12
US201762507531P 2017-05-17 2017-05-17
US62/507,531 2017-05-17
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210417996.0A Division CN114796236A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Publications (1)

Publication Number Publication Date
CN110177572A true CN110177572A (zh) 2019-08-27

Family

ID=59901615

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780055706.XA Pending CN110177572A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物
CN202210417996.0A Pending CN114796236A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210417996.0A Pending CN114796236A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Country Status (12)

Country Link
US (1) US10300077B2 (https=)
EP (1) EP3509639A1 (https=)
JP (1) JP2019526612A (https=)
KR (1) KR20190072521A (https=)
CN (2) CN110177572A (https=)
AU (1) AU2017322332A1 (https=)
BR (1) BR112019004540A2 (https=)
CA (1) CA3036511A1 (https=)
IL (1) IL265255A (https=)
MX (1) MX2019002673A (https=)
PH (1) PH12019500479A1 (https=)
WO (1) WO2018049141A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
CN101296691A (zh) * 2005-08-05 2008-10-29 努沃研究公司 透皮释药剂型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) * 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
CA2602386A1 (en) * 2005-03-25 2006-10-05 Merck & Co., Inc. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
CA2623839C (en) * 2005-09-26 2013-12-17 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
WO2008016768A1 (en) * 2006-08-02 2008-02-07 Roberta Diaz Brinton Phytoestrogenic formulations and uses thereof
BRPI1015472A2 (pt) * 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
WO2014194166A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
CN101296691A (zh) * 2005-08-05 2008-10-29 努沃研究公司 透皮释药剂型

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOWARD FILLIT等: "OBSERVATION S IN A PRELIMINARY OPEN TRIAL OF ESTRADIOL THERAPY FOR SENILE DEMENTIA-ALZHEIMER’S TYPE", 《PSYCHONEUROENDOCRINOLOGY》 *
何伋等主编: "《神经精神病学辞典》", 30 June 1998 *
王耀山等: "《神经系统疾病鉴别诊断学》", 31 May 2004 *
陆惠华 盛净主编: "《老年常见疾病临床手册》", 31 December 2006 *

Also Published As

Publication number Publication date
CN114796236A (zh) 2022-07-29
CA3036511A1 (en) 2018-03-15
IL265255A (en) 2019-05-30
WO2018049141A1 (en) 2018-03-15
JP2019526612A (ja) 2019-09-19
EP3509639A1 (en) 2019-07-17
US20180071316A1 (en) 2018-03-15
WO2018049141A4 (en) 2018-05-03
MX2019002673A (es) 2019-07-04
PH12019500479A1 (en) 2019-07-29
AU2017322332A1 (en) 2019-04-04
BR112019004540A2 (pt) 2019-05-28
US10300077B2 (en) 2019-05-28
KR20190072521A (ko) 2019-06-25

Similar Documents

Publication Publication Date Title
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
US5556847A (en) Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
US4835147A (en) Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
JP2001510471A (ja) アンドロゲン合成インヒビター
WO2004062606A2 (en) Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
CN110177572A (zh) 用于治疗痴呆的组合物
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
US11274118B2 (en) Progesterone analogs and uses related thereto
JP2016527307A5 (https=)
Huang et al. From dried bear bile to molecular investigation of differential effects of bile acids in ex vivo and in vitro models of myocardial dysfunction: Relevance for neuroinflammation
EP0676203A1 (fr) Composition pharmaceutiques des composés ayant une activité anti-glucocorticoide pour la prévention ou traitement des manifestations liées au syndrome de sevrage spontané ou précipité des narcotiques
EP1123100B1 (en) Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
JP2019526612A5 (https=)
EP2687215A1 (en) Mesterolone pharmaceutical composition for androgens' deficiencies in woman
Zhu et al. Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
DECKER Pregnenolone & Its Metabolites: Central Nervous System Effects.
EP4429669A1 (en) Steroid as a modulator of gabaa receptor
Maibach Effect of Single versus Multiple Dosing in Percutaneous Absorption
Freed Therapeutic use of testosterone in aqueous suspension
US20060135499A1 (en) Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal
GENAZZANI et al. methods, techniques, drugs
TWI455716B (zh) 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
US20060217357A1 (en) Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
Debled The menopause disease
KR20050077045A (ko) 엑스메스탄을 사용한 불임 치료법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190827

RJ01 Rejection of invention patent application after publication